AUG 22, 2018 Download PDF Agilent’s wholesale shift in its allegations, two and a half years into its suit, reveals only the weakness of its claims. Agilent’s most recent allegations are gamesmanship, not substance. They omit that more than four months before it sought to change its complaint, Twist informed – and provided to Agilent – the... Read more
Agilent Companion Diagnostic Gains Expanded FDA Approval in Urothelial Carcinoma PD-L1 IHC 22C3 pharmDx Now Approved to Identify Certain Urothelial Carcinoma Patients for Treatment With KEYTRUDA(R) (pembrolizumab) SANTA CLARA, Calif., August 21, 2018 Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its Dako PD-L1 IHC 22C3... Read more
Agilent Receives 2018 IBO Industrial Design Gold Award for the Ultivo Triple Quadrupole LC/MS System Award Received for Excellence in Industrial Design SANTA CLARA, Calif., August 20, 2018 Agilent Technologies Inc. (NYSE: A) announced today that it has received the 2018 IBO Industrial Design Gold Award for the Ultivo Triple Quadrupole LC/MS System from Instrument... Read more
Agilent Completes Acquisition of Young In Scientific Co. Ltd. Assets SANTA CLARA, Calif., Aug 17, 2018 Agilent Technologies Inc. (NYSE: A) today announced that it has completed its acquisition of the Agilent-related business from Young In Scientific Co. Ltd. and its affiliates (“YI Scientific”). YI Scientific is a leading distributor of analytical and scientific instruments... Read more
Agilent First to Release Software Supporting Standardized Data Format for Pharmaceutical Industry SANTA CLARA, Calif., August 8, 2018 Agilent Technologies Inc. (NYSE: A) announced today the release of a new version of its chromatography data system that enables laboratories to export files in the Allotrope Data Format (ADF), an emerging standard developed by a consortium... Read more
Agilent Announces Update on PD-L1 CE-IVD in Urothelial Carcinoma PD-L1 IHC 22C3 pharmDx Can Now Be Used as an Aid to Identify Urothelial Carcinoma Patients for Treatment With KEYTRUDA® (pembrolizumab) SANTA CLARA, Calif., August 8, 2018 Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx assay is now labeled for an... Read more
Agilent Technologies Completes Acquisition of ProZyme SANTA CLARA, Calif., Aug 1, 2018 Agilent Technologies Inc. (NYSE: A) today announced that it has completed the acquisition of ProZyme, Inc., a leading provider of glycan reagents, kits and standards. This acquisition expands Agilent’s portfolio of biopharma consumables. Founded in 1990, Hayward-Calif. based ProZyme is an industry leading... Read more
Agilent Announces CFO Transition Didier Hirsch to Retire Oct. 31Robert W. McMahon to Become Chief Financial Officer SANTA CLARA, Calif., July 31, 2018 Agilent Technologies Inc. (NYSE: A) today announced that Didier Hirsch, senior vice president and chief financial officer, has decided to retire on Oct 31, 2018. The company has appointed Robert W. McMahon,... Read more
By Mohamed Lamri| July 26th, 2018|Categories: News| Genohm has made further strides in education this month with two of our own becoming contributors at the Université Côte d’Azur at Nice in France, along with other physicians and academic professors, to MSc Biobanks and Complex Data Management. Idrees Samim, SLIMS Engineer, and Jean-Guillaume Baumann, SLIMS Field Application Specialist, will represent Genohm there on... Read more
Agilent Receives Sustainability Leadership Award Business Intelligence Group Recognizes Company’s Innovative Product Designs SANTA CLARA, Calif., July 23, 2018 Agilent Technologies Inc. (NYSE: A) today announced that it has earned the 2018 Sustainability Leadership Award from the Business Intelligence Group for its commitment to sustainability through innovative product design. The Leadership Award, judged by a... Read more